RLAY

Business Context and Reporting Period

Company: Relay Therapeutics, Inc. (RLAY)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Relay is a clinical-stage precision medicine company utilizing its proprietary Dynamo® platform, which combines computational and experimental technologies to discover small molecule therapies for oncology and genetic diseases. The company has no products approved for commercial sale and has not generated revenue from product sales.

Key Financial Metrics

Note: Revenue consists primarily of license and milestone payments from collaboration agreements. The company has no debt outstanding.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased by $15.5 million (61%) compared to 2023. This was primarily due to the recognition of $25.0 million in variable consideration under the Genentech Agreement in 2023, whereas only $10.0 million was recognized in 2024.
• Operating Expenses: Total operating expenses decreased by $16.1 million to $382.5 million. R&D expenses declined by $10.9 million due to the prioritization of specific pipeline programs.
• Financing Activities: The company raised significant capital in 2024, including a $218.2 million public offering in September and a $29.8 million private placement in January. Net cash provided by financing activities was $270.2 million.
• Collaboration Updates:
  • Elevar Agreement: In December 2024, Relay entered an exclusive global licensing agreement with Elevar Therapeutics for lirafugratinib (RLY-4008), receiving $7.7 million in upfront and material transfer payments.
  • Genentech Termination: The collaboration with Genentech for migoprotafib was terminated without cause effective January 7, 2025. No further milestones are expected.

Guidance, Outlook, and Risks

Outlook and Liquidity: Management believes cash, cash equivalents, and investments of $781.3 million as of December 31, 2024, are sufficient to fund operations into the second half of 2027. The company expects to continue incurring significant operating losses for the foreseeable future.

Clinical Pipeline Highlights:

• RLY-2608 (Lead Candidate): An allosteric, pan-mutant PI3Kα inhibitor. Interim data from the ReDiscover Trial (cut-off Nov 4, 2024) showed a median Progression-Free Survival (PFS) of 9.2 months and an Objective Response Rate (ORR) of 39% in the recommended Phase 2 dose cohort. The company intends to initiate a Phase 3 registrational study (ReDiscover-2) comparing RLY-2608 plus fulvestrant against capivasertib plus fulvestrant.
• New Programs: In June 2024, the company announced three new programs targeting vascular malformations, Fabry disease, and NRAS-mutated solid tumors.

Key Risks:

• Clinical Development: The company has never completed a large-scale pivotal trial. Failure in clinical trials or inability to enroll patients could delay or prevent approval.
• Capital Requirements: Substantial additional funding will be required to advance the pipeline and commercialize products. Failure to raise capital could force program delays.
• Regulatory Approval: No products are approved; regulatory approval is uncertain and costly.
• Intellectual Property: Reliance on co-owned IP with D.E. Shaw Research and potential challenges to patent validity.

Investor Verification Checklist

• Cash Runway: Verify the $781.3 million cash position and the assumption that it funds operations through mid-2027.
• RLY-2608 Phase 3 Initiation: Confirm the timeline and design for the upcoming ReDiscover-2 Phase 3 trial, including patient enrollment targets.
• Elevar Agreement Milestones: Review the $495 million potential milestone payments and royalty structure associated with the Elevar licensing deal.
• Genentech Termination Impact: Assess the financial impact of the Genentech agreement termination (effective Jan 2025) on future revenue streams.
• Stock Dilution: Monitor the $250 million "at-the-market" sales agreement with TD Securities and potential future equity offerings.